Caribou Biosciences, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Caribou Biosciences, Inc. | CRBU - NASDAQ |
$14.00-$16.00 | $16.00 | $17.65 | 19 million | 7/23/2021 |
| BofA Securities, Citigroup, SVB Leerink | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Terms Added 2021-07-19 Amended Terms 2021-07-22 | ||||||
Caribou Biosciences, Inc. Quote & Chart - Click for current quote - CRBU
IPO Boutique aggregates information on public companies and private companies, such as "CRBU" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Caribou Biosciences, Inc. (adapted from Caribou Biosciences, Inc. prospectus):
They are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying our novel CRISPR platform, CRISPR hybrid RNA-DNA, or chRDNA, pronounced “chardonnay,” toward the development of next-generation, genome-edited cell therapies.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying our novel CRISPR platform, CRISPR hybrid RNA-DNA, or chRDNA, pronounced “chardonnay,” toward the development of next-generation, genome-edited cell therapies.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "CRBU" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.